-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 ME+TZaeG0ESZPFCh6Ql2IPruZUkTltpfnASnotguXjt+pi45TykIQCJn0heWmla+
 RJD0L/lylOAt+AoOdh2kCw==

<SEC-DOCUMENT>0000950123-10-077317.txt : 20100813
<SEC-HEADER>0000950123-10-077317.hdr.sgml : 20100813
<ACCEPTANCE-DATETIME>20100813161022
ACCESSION NUMBER:		0000950123-10-077317
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20100813
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100813
DATE AS OF CHANGE:		20100813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		101015477

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c04995e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): August 13, 2010</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>0-50626</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>91-1707622</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>200 Connell Drive, Suite 1500<BR>Berkeley Heights, NJ<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>07922</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(908) 517-7330</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="justify" style="font-size: 10pt"><B>Item&nbsp;8.01 Other Events</B>


<P align="justify" style="font-size: 10pt; text-indent: 4%">On August&nbsp;13, 2010, Cyclacel Pharmaceuticals, Inc. (the &#147;<B>Company</B>&#148;) issued a press release announcing that it will
be holding a special stockholders&#146; meeting on October&nbsp;4, 2010 at which holders of record of its 6% Exchangeable
Convertible Preferred Stock (the &#147;<B>Preferred Stock</B>&#148;) as of the close of business on September&nbsp;15, 2010 will be entitled
to elect two directors. Pursuant to the Company&#146;s bylaws, any holder of at least 10% of the issued and outstanding
Preferred Stock has the right to nominate directors to fill the two director positions, which nominations must be
received by the Company&#146;s Secretary prior to the close of business on August&nbsp;23, 2010. A copy of the press release is
attached as Exhibit&nbsp;99.1.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>Item&nbsp;9.01</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify"><B>Financial Statements and Exhibits</B></DIV></TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">The following exhibit is furnished with this Report:</DIV></TD>
</TR>

</TABLE>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;No.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Description</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release dated August&nbsp;13, 2010</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="justify" style="font-size: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.


<P align="center" style="font-size: 10pt">


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left" valign="top"><B>CYCLACEL PHARMACEUTICALS, INC.</B></TD>
</TR>
<TR valign="bottom">
    <TD colspan="4">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Paul McBarron</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:<BR>
Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Paul McBarron<BR>
Executive Vice President&#151;Finance,<BR>
Chief Financial Officer and<BR>
Chief Operating Officer</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="justify" style="font-size: 10pt">Date: August&nbsp;13, 2010


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c04995exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: Arial,sans-serif; margin-left: .25in; width: 7.20in">

<P align="right" style="font-size: 10pt"><B>Exhibit 99.1</B>

<P align="center" style="font-size: 10pt"><B>PRESS RELEASE</B>

<P align="center" style="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS&#146; 6% CONVERTIBLE EXCHANGEABLE PREFERRED<BR>
STOCKHOLDERS REQUEST SPECIAL MEETING TO ELECT DIRECTORS</B>



<P align="left" style="font-size: 10pt"><B>BERKELEY HEIGHTS, NJ &#150; August&nbsp;13, 2010 &#150; </B>Cyclacel Pharmaceuticals, Inc. (Nasdaq: <U>CYCC</U> ) (Nasdaq:
<U>CYCCP</U>), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle
control for the treatment of cancer and other serious disorders (the &#147;Company&#148;), today reported that it has received a
request from a holder of at least 10% of its 6% Convertible Exchangeable Preferred Stock (the &#147;Preferred Stock&#148;) that
the Company call a special meeting of its holders of Preferred Stock to elect two directors to fill the vacancies on
the Company&#146;s board of directors. The vacancies were created pursuant to the terms of the Certificate of Designations
governing the Preferred Stock, which states that if the Company had not paid the dividends on its Preferred Stock for
six quarterly periods, the number of director positions on the Company&#146;s board of directors automatically increases by
two. This occurred as of August&nbsp;2, 2010.


<P align="left" style="font-size: 10pt">The holders of the Preferred Stock, voting as a separate class, are entitled to elect two directors to fill these two
vacancies at the Company&#146;s next stockholders&#146; meeting and at each annual stockholder&#146;s meeting thereafter until the
dividends are paid in full. Because the right to elect directors accrued to the holders of the Preferred Stock more
than 90&nbsp;days before the next annual meeting of stockholders, the Company has established October&nbsp;4, 2010 as the date
for a meeting of the Company&#146;s holders of Preferred Stock. Holders of record of the Preferred Stock as of the close of
business on September&nbsp;15, 2010, will be entitled to vote at such meeting. The Company expects to mail the notice of
meeting and proxy statement to the holders of Preferred Stock at a later date.


<P align="left" style="font-size: 10pt">Pursuant to the Company&#146;s bylaws, any holder of at least 10% of the issued and outstanding Preferred Stock has the
right to nominate directors to fill the two director positions, which nominations must be received by the Company&#146;s
Secretary prior to the close of business on August&nbsp;23, 2010. The Company&#146;s bylaws require that nominations be in
writing and include all information required by Regulation&nbsp;14A promulgated under the Securities Exchange Act of 1934,
as amended. In addition, any nomination must include the nominee&#146;s written consent to be named in the Company&#146;s proxy
statement as a nominee and his or her agreement to serve as a director, if elected. The Company&#146;s bylaws also require
that certain information be provided with respect to the stockholder making such nomination. Failure to follow the
procedures set forth in the Company&#146;s bylaws will result in the nomination being declared defective.


<P align="left" style="font-size: 10pt">In general, the Company&#146;s directors should satisfy the independence, diversity and other corporate governance criteria
of the NASDAQ Stock Market, Inc. and the Securities and Exchange Commission, and should have skills and experience that
will complement the Company&#146;s needs.




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Arial,sans-serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>About Cyclacel Pharmaceuticals, Inc.</B>


<P align="left" style="font-size: 10pt">Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control
for the treatment of cancer and other serious disorders. Three product candidates are in clinical development:
Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer.
Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the
treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an
Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel&#146;s ALIGN
Pharmaceuticals subsidiary markets directly in the U.S. Xclair&#174; Cream for radiation dermatitis, Numoisyn&#174; Liquid and
Numoisyn&#174; Lozenges for xerostomia. Cyclacel&#146;s strategy is to build a diversified biopharmaceutical business focused in
hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug
candidates. Please visit <U>www.cyclacel.com</U> for additional information.


<P align="left" style="font-size: 10pt"><B>Forward-looking Statements</B>


<P align="left" style="font-size: 10pt">This news release contains certain forward-looking statements that involve risks and uncertainties that could cause
actual results to be materially different from historical results or from any future results expressed or implied by
such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the
efficacy, safety, and intended utilization of Cyclacel&#146;s product candidates, the conduct and results of future clinical
trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering
activities. Factors that may cause actual results to differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or
later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated
with reliance on outside financing to meet capital requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and commercialization of product candidates. You are
urged to consider statements that include the words &#147;may,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;believes,&#148; &#147;estimates,&#148;
&#147;projects,&#148; &#147;potential,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;intends,&#148; &#147;continues,&#148; &#147;forecast,&#148; &#147;designed,&#148; &#147;goal,&#148; or
the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and
description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form
10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are
available at <U>www.sec.gov</U>. Such forward-looking statements are current only as of the date they are made, and
we assume no obligation to update any forward-looking statements, whether as a result of new information, future events
or otherwise.


<P align="left" style="font-size: 10pt"><B>Contact for Cyclacel Pharmaceuticals, Inc.</B>


<P align="left" style="font-size: 10pt">Investors/Media:
<BR>
Corey Sohmer, (908)&nbsp;517-7330
<BR>
<U>csohmer@cyclacel.com</U>


<P align="left" style="font-size: 10pt">&#169; Copyright 2010 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&#174; are trademarks
of Cyclacel Pharmaceuticals, Inc. Numoisyn&#174; and Xclair&#174; are trademarks of Sinclair Pharma plc.


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
